Catalyst Capital Advisors LLC Invests $1.94 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Catalyst Capital Advisors LLC acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The fund acquired 33,965 shares of the biopharmaceutical company's stock, valued at approximately $1,944,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. GAMMA Investing LLC lifted its position in Halozyme Therapeutics by 96.6% during the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 254 shares during the period. International Assets Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at $33,000. Whittier Trust Co. purchased a new stake in shares of Halozyme Therapeutics during the first quarter worth $27,000. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Halozyme Therapeutics during the second quarter worth $49,000. Finally, Toth Financial Advisory Corp purchased a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at $57,000. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Stock Performance

Shares of HALO stock traded up $0.25 on Tuesday, reaching $58.72. The stock had a trading volume of 1,140,102 shares, compared to its average volume of 1,288,751. The company has a 50 day simple moving average of $56.83 and a 200 day simple moving average of $52.42. The stock has a market cap of $7.44 billion, a P/E ratio of 19.44, a price-to-earnings-growth ratio of 0.50 and a beta of 1.29. Halozyme Therapeutics, Inc. has a 1 year low of $33.15 and a 1 year high of $65.53. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 41.43% and a return on equity of 179.82%. The business had revenue of $231.40 million for the quarter, compared to the consensus estimate of $204.94 million. During the same period in the prior year, the firm earned $0.68 EPS. The company's revenue for the quarter was up 4.7% compared to the same quarter last year. Equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.1 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on HALO shares. TD Cowen upped their price target on Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a "buy" rating in a report on Wednesday, August 7th. Morgan Stanley raised their target price on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an "overweight" rating in a report on Wednesday, August 7th. Benchmark reissued a "buy" rating and set a $60.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. Wells Fargo & Company lowered Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and raised their price objective for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. Finally, Cowen reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $61.11.

Insider Activity

In other Halozyme Therapeutics news, Director Matthew L. Posard sold 10,000 shares of the business's stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $55.72, for a total value of $557,200.00. Following the sale, the director now owns 89,755 shares of the company's stock, valued at $5,001,148.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Halozyme Therapeutics news, Director Matthew L. Posard sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $55.72, for a total value of $557,200.00. Following the sale, the director now owns 89,755 shares of the company's stock, valued at approximately $5,001,148.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Matthew L. Posard sold 9,881 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total transaction of $570,133.70. Following the completion of the sale, the director now owns 69,874 shares in the company, valued at $4,031,729.80. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 89,881 shares of company stock worth $5,169,834 over the last three months. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.